ACB
Price
$4.40
Change
-$0.13 (-2.87%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
256.29M
84 days until earnings call
Intraday BUY SELL Signals
MRMD
Price
$0.09
Change
-$0.01 (-10.00%)
Updated
Nov 12 closing price
Capitalization
35.6M
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACB vs MRMD

Header iconACB vs MRMD Comparison
Open Charts ACB vs MRMDBanner chart's image
Aurora Cannabis
Price$4.40
Change-$0.13 (-2.87%)
Volume$11.89K
Capitalization256.29M
MariMed
Price$0.09
Change-$0.01 (-10.00%)
Volume$934.78K
Capitalization35.6M
ACB vs MRMD Comparison Chart in %
ACB
Daily Signal:
Gain/Loss:
MRMD
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ACB vs. MRMD commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and MRMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ACB: $4.53 vs. MRMD: $0.09)
Brand notoriety: ACB: Notable vs. MRMD: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 39% vs. MRMD: 68%
Market capitalization -- ACB: $248.74M vs. MRMD: $35.95M
ACB [@Pharmaceuticals: Generic] is valued at $248.74M. MRMD’s [@Pharmaceuticals: Generic] market capitalization is $35.95M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileMRMD’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • MRMD’s FA Score: 0 green, 5 red.
According to our system of comparison, MRMD is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while MRMD’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 6 bearish.
  • MRMD’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MRMD is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а +1.57% price change this week, while MRMD (@Pharmaceuticals: Generic) price change was -18.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

ACB is expected to report earnings on Feb 05, 2026.

MRMD is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($256M) has a higher market cap than MRMD($35.6M). ACB YTD gains are higher at: 6.588 vs. MRMD (-22.176). ACB has higher annual earnings (EBITDA): 26.6M vs. MRMD (11.9M). ACB has more cash in the bank: 140M vs. MRMD (5.94M). MRMD has less debt than ACB: MRMD (87M) vs ACB (102M). ACB has higher revenues than MRMD: ACB (358M) vs MRMD (157M).
ACBMRMDACB / MRMD
Capitalization256M35.6M719%
EBITDA26.6M11.9M224%
Gain YTD6.588-22.176-30%
P/E Ratio19.44N/A-
Revenue358M157M228%
Total Cash140M5.94M2,358%
Total Debt102M87M117%
FUNDAMENTALS RATINGS
ACB vs MRMD: Fundamental Ratings
ACB
MRMD
OUTLOOK RATING
1..100
6355
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9295
PRICE GROWTH RATING
1..100
8065
P/E GROWTH RATING
1..100
8996
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (58) in the Pharmaceuticals Other industry is in the same range as MRMD (60) in the null industry. This means that ACB’s stock grew similarly to MRMD’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MRMD (100) in the null industry. This means that ACB’s stock grew similarly to MRMD’s over the last 12 months.

ACB's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as MRMD (95) in the null industry. This means that ACB’s stock grew similarly to MRMD’s over the last 12 months.

MRMD's Price Growth Rating (65) in the null industry is in the same range as ACB (80) in the Pharmaceuticals Other industry. This means that MRMD’s stock grew similarly to ACB’s over the last 12 months.

ACB's P/E Growth Rating (89) in the Pharmaceuticals Other industry is in the same range as MRMD (96) in the null industry. This means that ACB’s stock grew similarly to MRMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBMRMD
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signal:
Gain/Loss:
MRMD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CEBTF0.02N/A
N/A
Citychamp Watch & Jewellery Group Ltd.
ERVFF0.05N/A
N/A
Boron One Holdings Inc.
RTOBF3.60N/A
N/A
Ratos AB
BYCRF48.85N/A
N/A
Baycurrent Consulting Inc.
DRPRY5.39-0.01
-0.19%
DR ING H C F PORSCHE AG

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with SNDL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-0.44%
SNDL - ACB
65%
Loosely correlated
-3.24%
OGI - ACB
65%
Loosely correlated
-1.83%
CGC - ACB
64%
Loosely correlated
-0.83%
TLRY - ACB
62%
Loosely correlated
-4.65%
CRON - ACB
56%
Loosely correlated
+0.79%
More

MRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRMD has been loosely correlated with TSNDF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MRMD jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRMD
1D Price
Change %
MRMD100%
-9.34%
TSNDF - MRMD
45%
Loosely correlated
-8.59%
JUSHF - MRMD
43%
Loosely correlated
-10.77%
TCNNF - MRMD
41%
Loosely correlated
-0.86%
CRLBF - MRMD
40%
Loosely correlated
-4.13%
ACB - MRMD
39%
Loosely correlated
-0.44%
More